HLA-L and central nervous system leukemia: The clinical manifestations are based on primary disease such as leukocyte stasis syndrome, hyperviscosity syndrome, acute tumor lysis syndrome, etc. Patients with HLAL have a high early mortality rate [22], difficulty in complete remission, easy relapse after remission, and difficultly to induce remission after relapse, and it easily induces central nervous system leukemia.